We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Simple, Inexpensive Genetic Test Can Identify MS Patients at Risk of Fatal Brain Infection

By LabMedica International staff writers
Posted on 20 Mar 2023
Print article
Image: Leading MS/PML experts have recommended genetic testing to prevent fatal brain infection in MS patients (Photo courtesy of Pexels)
Image: Leading MS/PML experts have recommended genetic testing to prevent fatal brain infection in MS patients (Photo courtesy of Pexels)

Patients with multiple sclerosis (MS) are confronted with a difficult decision - whether they should take medications that have proven to be effective in slowing the disease's progression, despite the potential risk of triggering a fatal brain infection called progressive multifocal leukoencephalopathy (PML). This rare complication occurs when the JC virus, which is prevalent but usually dormant in most carriers, becomes active. Immune-modifying medications, including those prescribed for MS treatment, have been linked to PML in rare cases. As more potent immunosuppressive drugs become available, drug-induced PML is becoming increasingly common.

Now, leading MS experts are recommending genetic testing to identify MS patients with an increased likelihood of experiencing serious medication side effects. Joseph Berger, MD, MS Division Chief at the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA), and Hans-Peter Hartung, MD, Neurology Chair of Heinrich Heine University (Düsseldorf, Germany), have come out in support of a new study that confirms a strong link between four genetic mutations and PML. These mutations were found to be significantly more common in MS patients who took PML-linked drugs and later developed PML compared to those who took similar medications but did not develop PML.

"The availability of a simple, relatively inexpensive test that can identify the genes that put one at risk for PML would be enormously helpful in the management of patients. The widespread use of such testing could potentially allow the physician to use alternative therapies that do not carry the same risk of PML," stated Drs. Berger and Hartung.

Related Links:
University of Pennsylvania Perelman School of Medicine
Heinrich Heine University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.